# A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours

> **NCT04525638** · PHASE2 · UNKNOWN · sponsor: **Fundación de investigación HM** · enrollment: 30 (estimated)

## Conditions studied

- Neuroendocrine Tumours (NET)
- Neuroendocrine Carcinomas (NEC)

## Interventions

- **DRUG:** 177Lu-Dotatate
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT04525638
- **Lead sponsor:** Fundación de investigación HM
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-29
- **Primary completion:** 2024-09-30
- **Final completion:** 2024-09-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-08-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04525638

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04525638, "A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04525638. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*